PulsenmoreXTAE:PLSM 43 EBITDA Margin % is 11.73% as of Dec. 2025. GuruFocus rates XTAE:PLSM with a GF Score™ of 43/100 and a GF Value™ of ₪24.95 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 817 Medical Devices & Instruments companies, Pulsenmore ranks worse than 74.05% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Pulsenmore's EBITDA for the
six
months ended in Dec. 2025 was ₪4.23 Mil. Pulsenmore's Revenue for the
six
months ended in Dec. 2025 was ₪36.03 Mil. Therefore, Pulsenmore's EBITDA margin for the quarter that ended in Dec. 2025 was 11.73%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Pulsenmore EBITDA Margin % Related Terms
Pulsenmore EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Pulsenmore's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:PLSM vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Pulsenmore's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulsenmore EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulsenmore's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Pulsenmore's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulsenmore (XTAE:PLSM) has a EBITDA Margin % of 11.73% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pulsenmore and its competitors. According to the industry distribution chart, Pulsenmore ranks #605 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 74.1%.
Is Pulsenmore's EBITDA Margin % too high?
Pulsenmore's current EBITDA Margin % is 11.73%. The Medical Devices & Instruments industry median EBITDA Margin % is 7.44. Pulsenmore's value of 11.73% is 57.7% above this industry median. Based on the distribution chart, Pulsenmore ranks #605 out of 817 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Pulsenmore has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pulsenmore's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Pulsenmore ranks #605 out of 817 companies for EBITDA Margin %. This places Pulsenmore in the lower half of its industry. The industry median EBITDA Margin % is 7.44. Pulsenmore's value of 11.73% is 57.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pulsenmore's current EBITDA Margin % of 11.73% is 57.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pulsenmore and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulsenmore's current EBITDA Margin % is 11.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulsenmore stock overvalued right now?
Based on GuruFocus' analysis, Pulsenmore (XTAE:PLSM) is currently considered Possible Value Trap. The stock's GF Value™ is ₪24.95, compared to a current price of ₪10.14 — trading 59.4% below its estimated fair value. The current EBITDA Margin % is 11.73% and 57.7% above the Medical Devices & Instruments industry median of 7.44. Pulsenmore's overall GF Score™ is 43/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Pulsenmore (XTAE:PLSM), the current EBITDA Margin % is 11.73% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pulsenmore (XTAE:PLSM) Overvalued in 2026?
Based on GuruFocus' analysis, Pulsenmore stock appears to be undervalued.
The current stock price of ₪10.14 is trading 59.4% below its estimated GF Value™ of ₪24.95.
GuruFocus considers Pulsenmore to be Possible Value Trap.
Key valuation signals for XTAE:PLSM:
EBITDA Margin %: 11.73%
GF Value™: ₪24.95 vs. price of ₪10.14 (59.4% below fair value)
Industry Position: 57.7% above the Medical Devices & Instruments median (#605 of 817)
No single metric tells the full story. See the XTAE:PLSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.
43GF Score
Get the complete analysis for XTAE:PLSM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:PLSM has been successfully added to your 
